Endocrine Abstracts

The discovery of the RANK/RANKL/OPG axis provides opportunities for targeted interventions in a variety of skeletal disorders characterized by excessive bone resorption. In a proof of concept study, Bekker and colleagues demonstrated prompt, dose-related, reversible reduction in indices of bone turnover following subcutaneous administration of OPG-Fc in healthy adults. Inhibition of RANKL activity with denosumab, a fully human monoclonal IgG2 antibody that specifically inhibit...